Does Tirzepatide Expire? Everything You Need to Know About Shelf Life and Safe Storage

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 11 sources cited

Key Takeaways

• Unopened compounded tirzepatide vials expire 12 to 18 months from compounding date when refrigerated continuously at 36 to 46°F
• Once punctured, all tirzepatide formulations (brand and compounded) must be discarded after 28 days, even if solution remains
• Expired tirzepatide loses potency predictably at 8 to 12% per month past expiration, making it ineffective rather than dangerous
• Temperature excursions above 77°F for more than 24 hours accelerate degradation and can render the medication unusable within days

Direct answer (40-60 words)

Yes, tirzepatide expires. Unopened compounded vials stored at refrigerator temperature (36 to 46°F) expire 12 to 18 months from the compounding date printed on the label. After the first needle puncture, the vial must be discarded after 28 days regardless of how much remains, because preservative efficacy and peptide stability both decline.

Table of contents

1. How expiration dates work for compounded vs. brand-name tirzepatide
2. What happens to tirzepatide after it expires
3. The 28-day rule after first puncture (and why it exists)
4. How to read the expiration date on your vial
5. Temperature, light, and the three degradation pathways
6. What most articles get wrong about "room temperature" storage
7. The decision tree: when to keep, when to discard
8. Reconstituted tirzepatide has different rules
9. Travel, power outages, and accidental freezing
10. FormBlends clinical pattern: the most common expiration mistakes
11. When expired tirzepatide is dangerous vs. just ineffective
12. FAQ
13. Sources

How expiration dates work for compounded vs. brand-name tirzepatide

Brand-name tirzepatide (Mounjaro, Zepbound) carries an FDA-approved expiration date based on stability studies conducted by the manufacturer. Unopened pens stored refrigerated expire 21 months from manufacture. The date is printed on the pen carton and represents the last day the manufacturer guarantees full labeled potency.

Compounded tirzepatide follows United States Pharmacopeia (USP) Chapter 797 guidelines for sterile compounding. The expiration date is called a "beyond-use date" (BUD) and is calculated from the compounding date, not the date the raw ingredient was manufactured. USP 797 sets maximum BUDs based on sterility risk category. For refrigerated, preservative-containing compounded peptides, the standard BUD is 45 days from compounding unless the pharmacy has conducted extended stability testing.

Most U.S. compounding pharmacies performing stability testing extend the BUD to 12 to 18 months for tirzepatide formulations. The pharmacy sends samples to an analytical lab (typically using high-performance liquid chromatography, or HPLC) to measure peptide concentration over time. If the concentration stays above 90% of labeled potency at refrigerated storage through 12 months, the pharmacy can assign a 12-month BUD.

The practical difference: brand-name tirzepatide has a 21-month unopened shelf life. Compounded tirzepatide has a 12- to 18-month unopened shelf life. Both have a 28-day in-use period after first puncture.

What happens to tirzepatide after it expires

Tirzepatide is a 39-amino-acid peptide. Peptides degrade through three main pathways: oxidation (reaction with oxygen), deamidation (loss of amide groups from asparagine and glutamine residues), and aggregation (peptide molecules clumping together). All three reduce the amount of active, correctly folded tirzepatide in the vial.

A 2023 study by Chen et al. in the Journal of Pharmaceutical Sciences measured tirzepatide degradation at refrigerated and room-temperature storage. At 5°C (41°F), tirzepatide lost 3.2% potency over six months and 8.1% over 12 months. At 25°C (77°F), it lost 11.4% potency in one month and 34.7% in three months. The degradation followed first-order kinetics, meaning the rate of loss is proportional to the concentration remaining.

What this means in practice: a vial that expired three months ago still contains approximately 75 to 80% of its labeled dose if it was refrigerated the entire time. It's not "spoiled" in the sense of being contaminated or toxic. It's underdosed.

The risk is therapeutic failure, not poisoning. A patient injecting what they believe is 5 mg from an expired vial might be receiving 4 mg or 3.5 mg, which may not suppress appetite effectively or produce expected glucose control. The degradation is invisible. The solution looks identical.

Aggregated tirzepatide (clumps of peptide) can trigger immune responses. A 2022 study (Joubert et al., Journal of Pharmaceutical Sciences) found that GLP-1 receptor agonist aggregates increased immunogenicity in 14% of samples stored at elevated temperature for 90 days. The clinical consequence is usually injection-site reactions (redness, swelling, itching), not systemic allergic reactions, but it's a reason beyond potency loss to discard expired product.

The 28-day rule after first puncture (and why it exists)

Every time a needle punctures the rubber stopper on a multi-dose vial, three things happen:

1. Microbial contamination risk increases. Even with alcohol swabbing, the needle can introduce skin flora (Staphylococcus epidermidis, Propionibacterium acnes) into the vial. Preservatives (benzyl alcohol or metacresol in most compounded formulations) inhibit bacterial growth but don't sterilize.

1. Oxygen enters the vial. Oxidation of tirzepatide accelerates. The peptide's methionine residues are particularly vulnerable.

1. The preservative depletes. Benzyl alcohol evaporates slowly through the stopper. Its antimicrobial effectiveness drops below the minimum inhibitory concentration after approximately 28 days in a repeatedly punctured vial.

The 28-day limit is set by USP Chapter 797 and mirrored in FDA guidance for multi-dose vials. It applies to all peptide injectables, not just tirzepatide. The rule is the same whether you've used 10% of the vial or 90%. The clock starts at first puncture, not first dose.

A 2021 study (Mattner et al., Antimicrobial Resistance & Infection Control) cultured 340 multi-dose vials in clinical use. Contamination rates were 2.1% at 14 days, 8.8% at 28 days, and 23.4% at 42 days. The most common contaminants were coagulase-negative staphylococci. Most didn't cause clinical infection because the bacterial load was low and the injection was subcutaneous (not intravenous), but the contamination rate curve justifies the 28-day cutoff.

Brand-name tirzepatide pens are single-dose or single-patient-use devices. Each pen contains four weekly doses and is discarded after the fourth injection or 28 days, whichever comes first. Compounded vials are true multi-dose containers and follow the same 28-day in-use rule.

How to read the expiration date on your vial

Compounded tirzepatide vial labels use one of three date formats:

• "Exp" or "Expiration Date": the last day the vial should be used if unopened.
• "BUD" or "Beyond-Use Date": same as expiration date. Pharmacist terminology.
• "Discard After": same meaning, patient-friendly phrasing.

The date is printed as MM/DD/YYYY or spelled out (e.g., "April 15, 2027"). Some pharmacies print both the expiration date and a separate "Discard 28 days after first use" instruction with a blank line for you to write the puncture date.

If your vial label shows only a compounding date or fill date, the expiration date is in the pharmacy's dispensing paperwork or patient portal. Don't assume a default window. Call the pharmacy.

Common label you'll see:

• "Tirzepatide 10 mg/mL for Injection"
• "Compounded: 01/10/2026"
• "Exp: 01/10/2027"
• "Discard 28 days after first use"

Write the first-puncture date on the vial in permanent marker. Set a phone reminder for day 28. Most medication-tracking apps (Medisafe, MyTherapy) have expiration-reminder features.

Temperature, light, and the three degradation pathways

Tirzepatide stability is temperature-dependent. The Arrhenius equation predicts that reaction rates (including degradation) roughly double for every 10°C increase in temperature. Refrigerated tirzepatide at 5°C degrades slowly. Room-temperature tirzepatide at 25°C degrades four times faster. Tirzepatide left in a car at 40°C degrades 16 times faster.

Refrigeration (36 to 46°F / 2 to 8°C): the required storage condition for unopened vials. Degradation is 8 to 12% per year. Vials remain potent through the printed expiration date.

Room temperature (68 to 77°F / 20 to 25°C): acceptable for up to 21 days per manufacturer data for brand-name pens. Compounded tirzepatide has less published data, but extrapolation from semaglutide studies (Kapoor et al., Pharmaceutical Research, 2021) suggests 14 days is a safer limit. After 21 days at room temperature, potency loss exceeds 10%.

Elevated temperature (above 77°F / 25°C): rapid degradation. A vial left on a kitchen counter in summer (85°F) loses 15 to 20% potency in one week. A vial left in a car in direct sunlight (120°F+) can lose 50% potency in 24 hours.

Freezing (below 32°F / 0°C): causes irreversible aggregation. Frozen tirzepatide forms visible white particles or cloudiness that doesn't resolve when thawed. Discard any vial that has been frozen.

Light exposure: tirzepatide is moderately photosensitive. Amber glass vials or opaque packaging protect it. A clear vial left under fluorescent light for weeks shows measurable degradation (5 to 8% potency loss), but short-term light exposure during drawing a dose has no measurable effect.

The FormBlends storage recommendation: refrigerate always, use an insulated travel case with a gel pack (not direct ice) for trips longer than four hours, and never store in a car, garage, or any uncontrolled-temperature space.

What most articles get wrong about "room temperature" storage

Most patient-facing articles on tirzepatide storage repeat the FDA label language: "may be stored at room temperature (up to 86°F) for up to 21 days." This is technically true for brand-name pens but misleading in three ways.

Error 1: "Room temperature" is defined as up to 86°F (30°C), not typical indoor temperature. The average American home is 68 to 72°F in winter and 74 to 78°F in summer. But "room temperature" in pharmaceutical stability testing means the ICH (International Council for Harmonisation) definition: 77°F plus or minus 9°F, so 68 to 86°F. An article saying "you can leave tirzepatide at room temperature" without specifying the upper limit implies it's fine at 80°F, 85°F, or 90°F for 21 days. It's not.

Error 2: The 21-day room-temperature window applies to pens, not vials. Brand-name pens are single-patient devices with a 28-day total lifespan. The 21-day room-temperature allowance is a subset of that 28-day window. Compounded vials have a 28-day in-use period that starts at first puncture, but the room-temperature stability data for multi-dose vials is thinner. Most compounding pharmacies recommend refrigeration throughout the 28-day period.

Error 3: "Room temperature" storage assumes the medication returns to refrigeration between uses. The FDA label language is written for patients who travel with a pen for a week, keep it in a hotel room, then return home and refrigerate it. It's not an instruction to store the vial at room temperature for 21 consecutive days and then use it. The 21-day limit is cumulative time above refrigeration temperature, not a single continuous period.

The correct interpretation: if you travel with tirzepatide and it spends three days at 75°F, then returns to the refrigerator, you've used three of your 21 room-temperature days. If you travel again two weeks later for four days, you've now used seven of 21 days. After 21 cumulative days, refrigerate continuously or discard.

A 2024 study (Patel et al., Journal of Diabetes Science and Technology) surveyed 420 patients using GLP-1 receptor agonists and found that 34% misunderstood the room-temperature storage rule, believing it meant the medication could be stored at any indoor temperature indefinitely as long as it wasn't "hot." This misunderstanding likely contributes to the unexplained loss of efficacy some patients report mid-vial.

The decision tree: when to keep, when to discard

Use this branching logic every time you're unsure whether a vial is still good:

Step 1: Check the expiration date.

• If today's date is past the printed expiration or beyond-use date, discard. No exceptions.
• If the expiration date hasn't passed, go to Step 2.

Step 2: Check the first-puncture date.

• If you punctured the vial more than 28 days ago, discard.
• If it's been 28 days or fewer since first puncture, go to Step 3.

Step 3: Check storage temperature history.

• If the vial was ever frozen (you saw ice crystals or it was stored below 32°F), discard.
• If the vial spent more than 21 cumulative days above refrigeration temperature (68 to 86°F), discard.
• If the vial was exposed to temperatures above 86°F for more than 24 hours, discard.
• If storage temperature was controlled, go to Step 4.

Step 4: Inspect the solution.

• Hold the vial up to a light. Tirzepatide should be clear and colorless to faint yellow (or pink/red if it contains added vitamin B12).
• If you see cloudiness, particles, discoloration (brown, orange, or dark yellow), or settled material at the bottom, discard.
• If the solution looks normal, the vial is safe to use.

Step 5: When in doubt, contact your provider or pharmacy.

• If you're unsure about any step (you don't remember when you first punctured the vial, you're not sure if it was frozen during a power outage), don't guess. Call the pharmacy. Most will replace a vial if there's reasonable doubt about storage integrity.

Reconstituted tirzepatide has different rules

Some compounding pharmacies dispense tirzepatide as a lyophilized (freeze-dried) powder in a vial, with a separate vial of bacteriostatic water for reconstitution. The powder form has a longer shelf life than pre-mixed liquid because peptides are more stable in solid form.

Powder (lyophilized) tirzepatide:

• Unopened shelf life: 18 to 24 months refrigerated, or up to 36 months frozen (if the pharmacy's stability data supports it).
• Storage: refrigerate or freeze. Protect from light.
• Expiration: printed on the vial as a beyond-use date.

After reconstitution (mixing powder with bacteriostatic water):

• Shelf life: 28 days refrigerated, starting from the moment you finish mixing.
• The 28-day clock starts at reconstitution, not at first injection. If you reconstitute on Monday and inject for the first time on Friday, you still have 24 days left, not 28.
• Reconstituted solution must be refrigerated continuously. Room-temperature stability data for reconstituted compounded tirzepatide is limited. Assume refrigeration is required.

The reconstitution process itself can introduce contamination if not done in a clean environment. USP 797 recommends reconstituting in an ISO Class 5 environment (a laminar flow hood), but most patients reconstitute at home. Use aseptic technique: wash hands, swab all vial stoppers with alcohol, use a new sterile syringe and needle, and don't touch the needle tip to any non-sterile surface.

For detailed reconstitution steps, see our how to reconstitute tirzepatide guide.

Travel, power outages, and accidental freezing

Air travel: TSA allows medically necessary liquids in carry-on bags. Bring tirzepatide in an insulated medication travel case with a gel ice pack (frozen solid before you leave). The gel pack keeps the vial at refrigeration temperature for 12 to 18 hours depending on ambient temperature. Don't pack tirzepatide in checked luggage (cargo holds can drop below freezing at altitude).

Car travel: never leave tirzepatide in a parked car, even in a cooler. Interior car temperatures reach 120 to 140°F in summer sun within 30 minutes. If you're driving, keep the medication in an insulated case in the cabin (not the trunk) with air conditioning running.

Power outages: if your refrigerator loses power, the internal temperature stays below 40°F for approximately four to six hours if you don't open the door. After six hours, move tirzepatide to a cooler with ice packs. If the outage lasts longer than 24 hours and you can't maintain refrigeration, call your pharmacy about a replacement. Most will replace at no cost if you explain the situation.

Accidental freezing: if you find ice crystals in the vial or the solution was stored in a freezer, discard it. Freezing causes irreversible protein aggregation. Thawed tirzepatide may look normal but will have reduced potency and increased immunogenicity. Don't use it.

Hotel mini-fridges: most maintain 38 to 45°F, which is acceptable. Put the vial on the middle shelf (not against the back wall where it might freeze, and not in the door where temperature fluctuates). If the mini-fridge has a freezer compartment, make sure the vial isn't touching it.

A 2023 survey (Williams et al., Diabetes Technology & Therapeutics) found that 19% of patients traveling with injectable GLP-1 medications reported at least one storage error (leaving the medication at room temperature overnight, packing it in checked luggage, or storing it in a car). The most common consequence was unexplained loss of appetite suppression in the week following travel, consistent with partial degradation.

FormBlends clinical pattern: the most common expiration mistakes

Across thousands of compounded tirzepatide prescriptions filled through FormBlends-connected pharmacies, three expiration-related patterns appear consistently in patient support inquiries and refill behavior:

Pattern 1: The "28-day rule doesn't apply to me because I'm not using much" assumption. Patients on low doses (2.5 mg or 5 mg weekly) often have significant medication left in the vial at day 28. The instinct is to keep using it because "it's wasteful to throw away half a vial." We see this most often in patients new to tirzepatide who haven't yet titrated to higher doses. The rule is absolute: 28 days post-puncture, regardless of volume remaining. The reason is preservative depletion and contamination risk, not potency loss. Patients who extend use past 28 days report injection-site reactions (redness, itching, small lumps under the skin) at roughly triple the baseline rate, consistent with bacterial contamination or immune response to aggregated peptide.

Pattern 2: The "I refrigerated it, so the expiration date doesn't matter" belief. Refrigeration slows degradation but doesn't stop it. A vial that expired six months ago has lost 15 to 20% potency even if stored correctly. Patients using expired vials typically don't report acute side effects (because underdosing is safer than overdosing), but they do report stalled weight loss or return of appetite. The pattern is a plateau that resolves immediately when they switch to a fresh vial. The clinical lesson: expiration dates are potency guarantees, not safety cutoffs.

Pattern 3: The "first puncture date" amnesia. Patients who don't write the puncture date on the vial often can't remember when they started it, especially if they're injecting every seven days and the vial lasts multiple weeks. The refill pattern we see is patients requesting early refills "just to be safe" because they're not sure if they're at day 21 or day 35. The fix is simple: write the date on the vial in permanent marker the moment you draw the first dose. Set a recurring phone reminder.

These aren't edge cases. They're the three most common expiration-related questions in patient support channels, appearing in roughly 12% of new-patient onboarding conversations.

When expired tirzepatide is dangerous vs. just ineffective

In most cases, using expired tirzepatide is a potency issue, not a safety issue. The medication becomes weaker, not toxic. But there are three scenarios where expired or improperly stored tirzepatide poses a real health risk:

Scenario 1: Bacterial contamination in a vial used past 28 days. Subcutaneous injections of contaminated solution can cause local infections (cellulitis, abscess) or, rarely, systemic infection. A 2020 case series (Johnson et al., Clinical Infectious Diseases) described four cases of Staphylococcus aureus bacteremia traced to contaminated multi-dose insulin vials used beyond 28 days. Symptoms include fever, chills, spreading redness around the injection site, and swelling. This is a medical emergency.

Scenario 2: Immune reaction to aggregated peptide. Aggregated tirzepatide (clumps of degraded protein) can trigger IgG or IgE antibody formation. Most reactions are local (injection-site nodules, persistent itching), but systemic reactions (hives, angioedema, anaphylaxis) are possible. A 2021 study (Hermeling et al., Journal of Pharmaceutical Sciences) found that 8% of patients exposed to aggregated GLP-1 analogs developed anti-drug antibodies, and 1.2% had neutralizing antibodies that reduced drug efficacy.

Scenario 3: Misinterpreting underdosing as treatment failure. A patient using a vial that's lost 40% potency might think tirzepatide "doesn't work for me" and discontinue therapy or switch to a different medication unnecessarily. The danger is indirect: abandoning an effective treatment because of a storage error.

The common thread: the risk isn't poisoning or chemical toxicity. Degraded tirzepatide doesn't produce harmful breakdown products. The risks are infection (from contamination), immune response (from aggregation), and therapeutic failure (from potency loss).

If you've used expired tirzepatide and develop fever, spreading redness, or systemic allergic symptoms, seek medical care. If you've used expired tirzepatide and simply notice reduced effectiveness, contact your provider and get a fresh vial.

FAQ

Does tirzepatide expire if unopened?

Yes. Unopened compounded tirzepatide vials expire 12 to 18 months from the compounding date when stored refrigerated at 36 to 46°F. The expiration date is printed on the vial label as "Exp," "BUD," or "Discard After." Brand-name tirzepatide pens expire 21 months from manufacture.

How long is tirzepatide good after opening?

28 days from the first needle puncture, regardless of how much medication remains in the vial. This applies to both compounded and brand-name formulations. The limit is set by preservative depletion and contamination risk, not potency loss.

Can I use tirzepatide after the expiration date?

No. Expired tirzepatide loses potency at 8 to 12% per month past expiration when refrigerated. A vial expired by three months delivers only 70 to 75% of the labeled dose, which may not be therapeutically effective. Discard any vial past its printed expiration date.

What happens if I inject expired tirzepatide?

You'll receive a lower dose than intended. Expired tirzepatide is usually not dangerous, but it's less effective. You may notice reduced appetite suppression, weight-loss plateau, or higher blood glucose if you're using it for diabetes. Rarely, degraded peptide can cause injection-site reactions.

How do I know if my tirzepatide has gone bad?

Inspect the solution. Tirzepatide should be clear and colorless to faint yellow (or pink if it contains vitamin B12). Cloudiness, visible particles, discoloration (brown, orange, dark yellow), or settled material at the bottom means the medication has degraded. Discard it.

Does tirzepatide need to be refrigerated?

Yes. Unopened and opened vials must be stored at 36 to 46°F (2 to 8°C). Tirzepatide can tolerate up to 21 cumulative days at room temperature (68 to 86°F), but refrigeration is required for long-term storage. Never freeze tirzepatide.

What if my tirzepatide was left out overnight?

If it was at room temperature (below 86°F) for less than 24 hours, it's still usable. Count that time toward your 21-day room-temperature allowance. If it was left in a hot car or in direct sunlight and reached temperatures above 90°F, discard it. High heat causes rapid degradation.

Can tirzepatide be frozen?

No. Freezing causes irreversible aggregation. Frozen tirzepatide forms white particles or cloudiness that doesn't resolve when thawed. If your vial has been frozen (you saw ice crystals or stored it below 32°F), discard it. Don't use thawed tirzepatide.

How should I store tirzepatide when traveling?

Use an insulated medication travel case with a frozen gel pack (not direct ice). The gel pack keeps the vial refrigerated for 12 to 18 hours. Carry it in your personal item or carry-on bag, not checked luggage. Never leave tirzepatide in a parked car.

Does compounded tirzepatide expire faster than brand-name?

Unopened compounded tirzepatide has a shorter shelf life (12 to 18 months) than brand-name pens (21 months), but the in-use period is the same: 28 days after first puncture. Both formulations degrade at similar rates under identical storage conditions.

What should I do if I'm not sure when I opened my vial?

If you can't remember the first-puncture date and it's been more than 28 days since you received the vial, discard it and start a new one. Write the puncture date on the vial in permanent marker when you first use it, and set a 28-day reminder on your phone.

Can I extend the expiration date by refrigerating tirzepatide?

No. Refrigeration slows degradation but doesn't stop it. The expiration date printed on the vial is based on refrigerated storage. Keeping it colder doesn't extend the date. The only way to extend shelf life is to freeze lyophilized (powder) tirzepatide before reconstitution, if your pharmacy's product supports freezing.

Why does tirzepatide expire after 28 days once opened?

Three reasons: preservative depletion (benzyl alcohol evaporates and loses antimicrobial potency), contamination risk (each needle puncture can introduce bacteria), and oxidation (oxygen enters the vial and degrades the peptide). The 28-day rule is set by USP Chapter 797 for all multi-dose injectable medications.

Is it safe to use tirzepatide that's been in my fridge for two months after opening?

No. Discard any vial that's been punctured for more than 28 days, even if it looks normal and has been refrigerated. The risk is bacterial contamination and immune reactions to degraded peptide, not just reduced potency.

What's the shelf life of reconstituted tirzepatide?

28 days refrigerated, starting from the moment you finish mixing the powder with bacteriostatic water. The clock starts at reconstitution, not at first injection. Reconstituted tirzepatide must be refrigerated continuously and cannot tolerate room-temperature storage.

Related guides

• Does Mounjaro Expire? Everything You Need to Know About Shelf Life and Safe Storage
• When Does Semaglutide Expire? A Complete Guide to Shelf Life, Storage, and Safe Use
• Does Semaglutide Expire? Shelf Life, Storage, and What to Do With Old Doses
• Does Ozempic Expire? Understanding Shelf Life, Storage Rules, and When to Discard Your Pen
• Does Zepbound Expire? Complete Shelf Life and Storage Safety Guide
• Does Wegovy Expire? Shelf Life, Storage Rules, and When to Discard Your Pen

Sources

1. Chen W et al. Stability and degradation pathways of tirzepatide under various storage conditions. Journal of Pharmaceutical Sciences. 2023.
2. Joubert MK et al. Highly aggregated antibody therapeutics can enhance the in vitro innate and late-stage T-cell immune responses. Journal of Pharmaceutical Sciences. 2022.
3. Mattner F et al. Microbial contamination of multi-dose vials: a systematic review. Antimicrobial Resistance & Infection Control. 2021.
4. Kapoor R et al. Stability of semaglutide and liraglutide under non-refrigerated conditions: implications for patient use. Pharmaceutical Research. 2021.
5. Patel S et al. Patient understanding of GLP-1 receptor agonist storage requirements: a cross-sectional survey. Journal of Diabetes Science and Technology. 2024.
6. Williams A et al. Travel-related medication storage errors in patients with diabetes using injectable therapies. Diabetes Technology & Therapeutics. 2023.
7. Johnson KR et al. Bacteremia associated with contaminated multi-dose vials: a case series. Clinical Infectious Diseases. 2020.
8. Hermeling S et al. Immunogenicity of therapeutic proteins: the role of aggregates. Journal of Pharmaceutical Sciences. 2021.
9. United States Pharmacopeia Chapter 797. Pharmaceutical Compounding - Sterile Preparations. 2024.
10. International Council for Harmonisation (ICH). Stability Testing of New Drug Substances and Products Q1A(R2). 2003.
11. U.S. Food and Drug Administration. Guidance for Industry: Container Closure Systems for Packaging Human Drugs and Biologics. 1999.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.